Views & Analysis Unstable and unpredictable? The reality of the PPRS Has the UK PPRS scheme met its five objectives?
Views & Analysis Just how much does the NHS spend on medicines? Confidential discounts and the PPRS pricing system are making it more difficult to arrive at an accurate figure.
Views & Analysis Three NICE thresholds for cost-effectiveness: does that make... NICE wants a new, third threshold for rare disease drugs - but what's the evidence behind it?
Views & Analysis The PPRS medicines pricing scheme: is it working for both si... The PPRS has now reached the half-way stage - a look at the stats so far.
Views & Analysis International benchmarking and NICE Is NICE willing to change, or is it inflexible? It is being pressed to compare itself to other HTA organisations.
Views & Analysis Sitting uncomfortably? The UK’s PPRS and statutory schemes Do the PPRS and the statutory scheme run effectively in parallel?
News Ex-BioNTech execs launch 'AI-native' cancer company Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
